A Phase 2 interventional study of NI-0101 and Placebo in Rheumatoid Arthritis, sponsored by Light Chain Bioscience - Novimmune SA. Completed at 19 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.
Sponsored by Light Chain Bioscience - Novimmune SA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Arthritis, Rheumatoid with a site in Georgia — 6 open to participants now, 10 under way, none of them phase 3. Arthritis, Rheumatoid · Georgia.
Among the 34 studies in Arthritis, Rheumatoid with a site in Georgia, this one is the 23rd largest by enrollment, is one of 2 that started in 2017, is one of 21 in phase 2, and was the 14th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →6 of the 34 studies in Arthritis, Rheumatoid with a site in Georgia are open now. Recruiting first, the newest first:
PTC Therapeutics · Sites in Georgia, United States, Mauritius and 1 more country
Ages 18–70
SciRhom GmbH · Sites in Georgia, Moldova, Romania
Ages 18–60
Merck Sharp & Dohme LLC · Sites in Georgia, Australia, Belgium and 8 more countries
Ages 18–75
Xencor, Inc. · Sites in Georgia, Moldova, New Zealand
Ages 18+
Lifordi Immunotherapeutics, Inc. · Sites in Georgia, Australia, Moldova and 2 more countries
Ages 18–75 · Healthy volunteers
A study can be open while its sites in Georgia have not opened yet or have stopped. Only those recruiting at a site in Georgia →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 90 is close to the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 135 across the 34 interventional studies. Of the 24 that completed or were terminated, 13 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 34 have an industry lead sponsor. The 10 most frequent:
Light Chain Bioscience - Novimmune SA is the lead sponsor of 9 studies on the registry; 1 is open to participants now.
Light Chain Bioscience - Novimmune SA has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
4 of the studies in Arthritis, Rheumatoid with a site in Georgia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06902519Gilead SciencesStudy of GS-0151 in Participants With Rheumatoid Arthritis | 2027-03 |
| NCT07207954Lifordi Immunotherapeutics, Inc.Study of LFD-200 in Healthy Adults and Adults With Moderate to Severe Rheumatoid Arthritis | 2027-07-16 |
| NCT06754462Immunovant Sciences GmbHA Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis | 2027-09 |
| NCT07779616PTC TherapeuticsStudy of PTC844 in Participants With Active Rheumatoid Arthritis | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 34 studies in Arthritis, Rheumatoid with a site in Georgia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 2, PoC, randomized, placebo-controlled, double blind, international multicentre study to explore the effect of a new antibody to treat patients with Rheumatoid Arthritis
The study foresees the randomization of at least 81 moderate to severe, ACPA positive, RA patients who are inadequate responders to MTX, in two double blind arms (NI-0101:placebo, with a ratio of 2:1). Patients will receive NI-0101 or placebo infusions up to a maximum of 6 administrations (every two weeks for 12 weeks). All patients will continue receiving a stable dose of MTX. After 12 weeks, patients will enter the follow up period with monthly visits for a minimum of 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A therapeutic humanized monoclonal antibody, administered by intravenous infusion every 2 weeks.
Drug: NI-0101
The placebo matches NI-0101 without active ingredient, administered by intravenous infusion every 2 weeks.
Other: Placebo
Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
Placebo
Incidence, severity, causality and outcomes of Adverse Events (AEs)
Incidence, severity, causality and outcomes of Adverse Events (AEs) (serious and non-serious), with particular attention being paid to infusion-related reactions and infections
Time frame: From screening up to 24 weeks after first treatment administration
Withdrawal for safety reasons
Time frame: From randomization up to 24 weeks after first treatment administration
Evolution of laboratory parameters
Time frame: From screening up to 24 weeks after first treatment administration
Level of potential circulating antibodies against NI-0101
Level of potential circulating antibodies against NI-0101 to determine immunogenicity; i.e. the development of anti-drug antibodies (ADA).
Time frame: From screening up to 24 weeks after first treatment administration
Levels of CRP
Levels of C-Reactive protein (CRP)
Time frame: From screening up to 24 weeks after first treatment administration
Levels of inflammatory cytokines/chemokines
IL-6, TNFa, IP-10, MCP-1, sICAM, CXCL13
Time frame: From screening up to 24 weeks after first treatment administration
DAS28 CRP
Measure of Disease Activity Scores (DAS) for Rheumatism in 28 tender or swollen joints and C-Reactive protein (CRP) - DAS28-CRP
Time frame: From screening to 24 weeks after first treatment administration
ACR criteria
Proportion of patients achieving American College of Rheumatology Criteria (ACR20, ACR50 and ACR70)
Time frame: From randomization to 24 weeks after first treatment administration
Proportion of patient achieving remission
Proportion of patient achieving remission (defined as DAS28 \< 2.6)
Time frame: From randomization to 24 weeks after first treatment administration
EULAR response
Proportion of patients achieving European League Against Rheumatism (EULAR) response criteria - good, moderate and no response
Time frame: From randomization to 24 weeks after first treatment administration
Joint Count
Mean number of Tender Joint Count/Swollen Joint Count.
Time frame: From screening to 24 weeks after first treatment administration
SDAI score
Mean improvement from baseline in Simplified Disease Activity Index (SDAI) score
Time frame: From randomization to 24 weeks after first treatment administration
HAQ-DI score
Mean improvement from baseline in the Health Assessment Questionnaire without Disability Index (HAQ-DI) score
Time frame: From randomization to 24 weeks after first treatment administration
SF-36 score
Mean improvement from baseline in 36-Item Short-Form Health Survey (SF-36) score
Time frame: from randomization to 24 weeks after first treatment administration
DAS28-ESR
Measure of Disease Activity Scores (DAS) for Rheumatism in 28 tender or swollen joints and Erythrocyte Sedimentation Rate (ESR) levels - DAS28-ESR
Time frame: From screening to 24 weeks after first treatment administration
CDAI score
Mean improvement from baseline in Clinical Disease Activity Index (CDAI) score scores
Time frame: From randomization to 24 weeks after first treatment administration
Exploratory PK analysis - Cmax
Peak drug plasma concentration (Cmax)
Time frame: From randomization to 24 weeks after first treatment administration
Exploratory PK analysis - Tmax
Time when plasma concentration is at peak (Tmax)
Time frame: From screening up to 24 weeks after first treatment administration
Exploratory PK analysis - Ctrough
Plasma drug concentration immediately prior next dosing (Ctrough)
Time frame: From randomization to 24 weeks after first treatment administration
Exploratory PK analysis - AUC
Area under the plasma concentration versus time curve (AUC)
Time frame: From randomization to 24 weeks after first treatment administration
Exploratory PK analysis - CL
Systemic drug clearance (CL)
Time frame: From randomization to 24 weeks after first treatment administration
Ran from May 2017 to primary completion in Jun 2018, 13 months.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 13 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NI-0101
Light Chain Bioscience - Novimmune SA